Amundi Acquires 311,034 Shares of Boston Scientific Corporation $BSX

Amundi lifted its holdings in Boston Scientific Corporation (NYSE:BSX) by 2.6% in the first quarter, Holdings Channel reports. The fund owned 12,308,715 shares of the medical equipment provider’s stock after purchasing an additional 311,034 shares during the quarter. Amundi’s holdings in Boston Scientific were worth $1,212,408,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. GAMMA Investing LLC raised its holdings in shares of Boston Scientific by 11,720.3% in the first quarter. GAMMA Investing LLC now owns 2,577,887 shares of the medical equipment provider’s stock worth $260,057,000 after buying an additional 2,556,078 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Boston Scientific by 18.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,839,362 shares of the medical equipment provider’s stock valued at $968,172,000 after acquiring an additional 1,709,461 shares during the period. Vanguard Group Inc. grew its position in Boston Scientific by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock valued at $13,577,311,000 after acquiring an additional 1,697,945 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Boston Scientific by 18.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock valued at $1,070,387,000 after acquiring an additional 1,664,108 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in Boston Scientific by 161.9% in the first quarter. Assenagon Asset Management S.A. now owns 2,485,696 shares of the medical equipment provider’s stock worth $250,757,000 after purchasing an additional 1,536,663 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the firm’s stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the transaction, the director directly owned 18,479 shares in the company, valued at approximately $1,959,328.37. This represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 124,214 shares of company stock worth $13,125,957 over the last 90 days. Company insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on BSX shares. Oppenheimer raised their price target on shares of Boston Scientific from $110.00 to $118.00 and gave the stock a “market perform” rating in a research note on Thursday, July 24th. Erste Group Bank upgraded shares of Boston Scientific to a “strong-buy” rating in a research note on Thursday, May 8th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Boston Scientific in a research report on Thursday, July 24th. Morgan Stanley boosted their price target on Boston Scientific from $120.00 to $125.00 and gave the company an “overweight” rating in a report on Friday, May 16th. Finally, Truist Financial increased their price objective on Boston Scientific from $120.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, July 24th. Three analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $117.50.

Boston Scientific Stock Up 1.1%

Shares of NYSE BSX opened at $106.61 on Wednesday. Boston Scientific Corporation has a 12-month low of $80.50 and a 12-month high of $108.94. The stock’s fifty day simple moving average is $104.65 and its two-hundred day simple moving average is $102.14. The stock has a market capitalization of $157.97 billion, a PE ratio of 63.46, a price-to-earnings-growth ratio of 2.54 and a beta of 0.65. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business’s revenue for the quarter was up 22.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.